TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV
Study: NCT02016248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy as a Boost
Description: The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
Study: NCT02318056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquacel® Ag Burn Glove
Description: burn dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Transfer Ag
Description: burn dressing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic
Description: antibiotic burn dressing
Study: NCT04201743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acellular amniotic membrane derived allograft injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acellular amniotic membrane derived allograft injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV
Study: NCT03859284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flowable resin composite
Description: gold standard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self adhering flowable
Description: moist bonding self adhering flowable composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self adhering flowable with adhesive
Description: moist bonding self adhering flowable composite with the aid of an adhesive system.
Study: NCT01516827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Description: TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
Study: NCT01686568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT05314673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Intra-lesional Bevacizumab Injection in primary pterygium
Description: The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium surgery without adjunctive therapy
Description: The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture
Study: NCT03862027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Balloon catheter
Description: Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP.
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV
Study: NCT02560805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV
Study: NCT01523080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg
Study: NCT01190930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, PO, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03424161

Intervention type: DEVICE
Group type: OTHER
Intervention: Secret RF
Description: Subjects will receive treatment with the Secret RF device
Study: NCT01190930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05569135

Intervention type: DEVICE
Intervention: Laser ablation
Description: A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
Study: NCT02909868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BackBeat-PHC
Description: A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
Study: NCT00541983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
Study: NCT02002143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Appointments
Description: Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Appointments (IAs)
Description: Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life.
Study: NCT03184844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: thalidomide:50mg/d p.o at bedtime
Study: NCT01561287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermal Autograft
Description: Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AlloDerm
Description: The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
Study: NCT03614936

Intervention type: OTHER
Intervention: Geriatric Screening Test G8
Description: Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).

Intervention type: OTHER
Intervention: Geriatric fragility test GERICO
Description: GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)
Study: NCT03813030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of lidocaine
Description: Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)
Description: Topical application in dermal-sampling visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)
Description: Intravenous infusion in clearance visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal open flow microperfusion
Description: Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Microdialysis
Description: Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Microdialysis
Description: Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in dermal sampling visit
Description: 1 sample is taken pre-dose and 12 samples are taken post-dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in dermal sampling visit
Description: 1 sample is taken pre-dose and 12 samples are taken post-dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in clearance visit
Description: 1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
Study: NCT00470496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo laser light exposure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery
Study: NCT03205579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Using video for educate cancer pain patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: Face to face cancer pain education by trained nurse
Study: NCT03537040

Intervention type: OTHER
Group type: OTHER
Intervention: Method of Levels
Description: Talking Therapy
Study: NCT00864240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex TM (Clobetasol) 0.05% Lotion, single exposure
Description: Subjects received Galderma Laboratories, L.P. formulated products
Study: NCT01920802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5mg BID up to 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: 6 mg BID up to 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID up to 4 weeks
Study: NCT03624816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: hyaluronic acid dermal filler gel
Study: NCT01912755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% articaine with 1:100,000 epinephrine
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
Study: NCT02633540

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT Radiation
Description: Radiation to Larynx
Study: NCT03048630

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Owner-to-Worker training about reducing chemical exposures in nail salons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Owner-to-Worker training about reducing chemical exposures in nail salons
Study: NCT00661583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed